Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C

Table 2 Aminoacid substitutions in HCV NS5B polymerase region associated with resistance to DAAs^a in treatment-naïve patients

R^b	P^c	D^d	M^e	Drug	G 1a (n = 21)	G 1b (n = 21)	G 2a (n = 2)	G 2c (n = 60)	G 3a (n = 20)	G 4d (n = 25)	G 4 k (n = 1)
NS5B	316	C	N,Y,H	Sofosbuvir, Mericitabine	•	^*C(57)/N(38),H(5)	•	•	•	•	•
NS5B	282	S	T	Sofosbuvir, Mericitabine	•	•	•	•	•	•	•
NS5B	320	I		Sofosbuvir, Mericitabine	•	•	•	•	•	•	•
NS5B	321	V		Sofosbuvir, Mericitabine	•	•	•	•	•	•	•

^a direct acting antiviral agents
R^b, Region; P^c, Position aa; D^d, Dominant aa; M^e, Mutant aa; (Donaldson, [29]; Lam, [25]; Tong, [28])
*Percentage of sequences with substitutions
•The dominant residue is found in 100 % of analyzed sequences for each genotype

ISSN: 1743-422X